Daily Stock List
Discount Dental Materials, Inc. (DDOO)
Today we are reporting on Discount Dental Materials, Inc. (DDOO), here at the QualityStocks Daily Newsletter.
Incorporated in Nevada on December 17, 2007, Discount Dental Materials, Inc. involves in the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. Their planned products include a medical device solution and a synthetic drug solution. The Company will conduct their operations via their wholly owned subsidiary Cerebain Biotech Corp. Discount Dental Materials has their headquarters in Dallas, Texas.
An early-stage drug development company, Cerebain Biotech concentrates on the treatment of Alzheimer's disease. This subsidiary develops disease-arresting biological agents using Omentum, which is naturally found in the human body. United States Patent Application Serial No. 13/309-468 (Patent), takes a novel approach through developing a disease-arresting drug in comparison to the present disease-inhibitors available today. Cerebain has the exclusive worldwide license rights for the Patent.
Clinical studies have proven that Omentum has biological agents that are regenerative. These agents exercise a favorable affect on the human brain. Cerebain Biotech's approach taps the Omental tissue without major surgery. Their Patent describes diverse methods of harvesting this agent from Omentum and administering it to the patients. It covers all potential ways of extracting the "brain booster". The Patent also covers pioneering methods of administering it to patients.
The long-term business plan of the Cerebain subsidiary is to explore the biochemical nature of this neurotrophic agent by basic research; develop medical devices described in the Patent, to continuously deliver the "brain booster" for sustained effect, as well as develop an injectable form of this agent.
Today, Discount Dental Materials’ Cerebain Biotech subsidiary announced that medical device product development company, Sonos Models, Inc., is ready to obtain pig omentum for testing the first Prototypes of the Company’s medical device product for treatment of Alzheimer’s.
Mr. Eric Clemons, Cerebain’s President, stated “We are enthusiastic with the pending acquisition of this animal omentum. We have decided to utilize the pig’s omentum in these tests because they are functionally analogous to humans. Our device is being developed to provide recurring omentum stimulation, a novel approach to the treatment for patients suffering from Alzheimer’s disease. We expect these tests to begin between December of this year and January of next year.”
Discount Dental Materials, Inc. (DDOO), closed Tuesday’s trading at $0.485, up 21.25%, on 145,500 volume with 41 trades. The average volume for the last 60 days is 17,727 and the stock's 52-week low/high is $0.13/$1.50.
TranSwitch Corp. (TXCC)
StreetInsider, UltimatePennyStock, Greenbackers, and Stock Analyzer reported earlier on TranSwitch Corp. (TXCC), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
TranSwitch Corp. is a leading provider of semiconductor solutions in the fast growing consumer electronics and telecommunications markets. The Companyprovides ground-breaking integrated circuit (IC) and intellectual property (IP) solutions. These solutions deliver core functionality for video, voice, and data communications equipment for the customer premises and network infrastructure markets. TranSwitch has their headquarters in Shelton, Connecticut.
TranSwitch’s mission is to help OEMs and ODMs to transform best-in-class voice and video quality for the next generation multimedia over IP. This is while providing the complete software platform and customer support needed for the quickest time-to-market. The Company’s customers are leading consumer electronics and telecommunications equipment companies around the world. TranSwitch has a wide-ranging portfolio of IP products, and international patents held in 22 countries.
Their solutions serve broadband wireless and wireline markets. The Company’s specialities comprise IC & IP solutions for HDTV and 3D-TV High Speed Interconnect; Communications Processors-based solutions for IP Multimedia CPE; and Multicore Processor SoC and software solutions for Fixed, 3G/LTE/4G Mobile Infrastructure.
For the customer-premises market, they provide multi-standard, high-speed interconnect solutions. These enable the distribution and presentation of high-definition (HD) video and data content for consumer electronics applications. TranSwitch also provides a family of best-in-class communications processors. Pertaining to the network infrastructure market, TranSwitch provides integrated multi-core network processor System-on-a-Chip (SoC) solutions. These solutions are for Fixed, 3G and 4G Mobile, VoIP, as well as Multimedia applications.
The Company offers their High-Definition Video High Speed Interconnect solution. TranSwitch offers High Speed Interconnects for full-rate 3D video and 4Kx2K displays. Their patented MHDP™ technology was developed for High Definition Television (HDTV) and 3-Dimensional Television (3D-TV). MHDP™ technology is capable of supporting HDMI™ 1.4, DisplayPortTM, MHLTM 2.1, and MyDPTM 1.0 specifications with only one connector. MHDPTM provides “four solutions on one port”.
In addition, TranSwitch provides their AnyCable® technology. This is the industry's highest-performance receiver that can work with any low-cost HDMI™ cable. AnyCable® technology lessens the total cost of HDMI solutions.
TranSwitch Corp. (TXCC), closed at $0.205, down 2.38%, on 159,129 volume with 48 trades. The average volume for the last 60 days is 184,484 and the stock's 52-week low/high is $0.15/$0.30.
The Radiant Creations Group, Inc. (RCGP)
PennyStocks24 and Penny Stocks Profile reported this month on The Radiant Creations Group, Inc. (RCGP), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
The Radiant Creations Group, Inc. engages in the development of different skin protection and hydration, anti-aging, liver health, weight balance, and Over-the-Counter (OTC) products. The Company has achieved breakthroughs creating these products through combining DNA technologies developed in the Western World and naturally acting traditional Chinese medicine ingredients believed never before used in western culture by any bioscience business. OTCQB-listed, The Radiant Creations Group is based in Lake Park, Florida.
Among the Company’s discoveries is a new mechanism of defense against skin deterioration and damage caused by sun exposure to ultraviolet (UV) light using the nucleotides, four "code molecules" extracted from DNA. This innovative mechanism also has major significance and value in many other cosmetic and non-cosmetic applications requiring UV protection. This mechanism is among The Radiant Creations Group’s licensed patented intellectual property (IP). The technology will undergo implementation across many unique product lines.
The Company provides day creams and anti-aging night creams. In addition, they provide weight control and weight loss products, as well as liver detoxifiers. Revivasol is their skin care product line. This is an anti-aging and revitalizing cream. The Company also has their Acne Gone. This is an OTC acne treatment cream. Additionally, their products include Deep Wrinkle Repair Cream; Nucleotide Sun Protection Cream, and Sport Block.
In BioSalts, their products include Weight Control, Weight Loss, and Detoxifier. The BioSalt products derive from selected ingredients from proven ancient Chinese Herbal food supplements and extracts to naturally aid in liver health.
Last week, The Radiant Creation Group announced the formation of their United Kingdom (UK) Subsidiaries. The Company has created three United Kingdom Corporations named Radiant Creations UK I, Radiant Creations UK II, and Radiant Creations UK III. The formation of these three subsidiaries is in direct correlation to the launching of the Company’s Direct to Consumer Model scheduled for this month.
The Radiant Creation Group’s intention is to emphatically expand the recently completed Revivasol product into the UK and European Union (EU) marketplaces.
The Radiant Creations Group, Inc. (RCGP), closed Tuesday’s trading session at $0.185, up 8.82%, on 503,410 volume with 98 trades. The average volume for the last 60 days is 1,591 and the stock's 52-week low/high is $0.06/$0.43.
Fuse Science, Inc. (DROP)
Xtremepicks, PennyStocks24, and OurHotStockPicks reported on Fuse Science, Inc. (DROP), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Fuse Science, Inc. is a consumer products and delivery technology company. Fuse holds the rights to new, patent-pending technologies prepared to redefine how consumers receive energy, medicines, vitamins, and minerals. The design of their technology is to speed up conveyance of medicines or nutrients relative to traditional pills and liquids. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents. Fuse Science has their headquarters in Miami Lakes, Florida.
Sublingual and transdermal delivery systems for bioactive agents can now, for the first time, effectively encapsulate and charge many different molecules to produce complete product formulations. These can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form applied under the tongue. The Company’s technology can enhance how consumers receive these products. ENERJEL™ is Fuse Science’s first topical product. Their PowerFuse™ is the Company’s first energy formula in a drop.
Fuse Science plans to commercialize their proprietary technology with a two-part strategy. One part of the strategy is the commercialization of select sports nutrition and performance products that highlight the efficacy and ease of use to consumers, leveraging the voice of and endorsement collaborations with well-known athletes to drive brand and product awareness. The second part of their strategy is targeted licensing of the proprietary technology into major Over-the-Counter (OTC) and pharmaceutical categories in which the delivery system offers superior product efficacy and consumption.
The Company’s ENERJEL™ utilizes elements of their unique delivery system. The proprietary formulation helps fatigued muscles feel energized. ENERJEL™ is applied topically to deliver sustained relief and an energized feeling. ENERJEL™ contains all natural ingredients. These include white willow bark and caffeine.
Their PowerFuse™ is administered fast and easily in the mouth. ElectroFuse™ is the Company's first electrolyte formula in a drop. It also is administered quickly and easily in the mouth. ElectroFuse™ allows for optimal absorption of the electrolytes for more immediate replenishment and effect. ElectroFuse™ contains natural ingredients and it has zero calories.
Last week, Fuse Science announced that MusclePharm Corp. has become a strategic investor in the Company. MusclePharm® is a leading sports nutrition company offering vitamins and nutritional supplements. In addition to MusclePharm, a number of other prominent investors participated in the financing.
Fuse Science, Inc. (DROP), closed Tuesday’s session at $0.0325, down 17.72%, on 5,136,764 volume with 253 trades. The average volume for the last 60 days is 1,415,296 and the stock's 52-week low/high is $0.038/$0.28.
A.P. Pharma, Inc. (APPA)
Profit Confidential, Stock Analyzer, Real Pennies, Stock Stars, MonsterStocksPicks, SmallCap Network, PennyStocks24, NYC Marketing Inc, The Street, and TopStockAnalysts reported on A.P. Pharma, Inc. (APPA), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
A.P. Pharma, Inc. is a specialty pharmaceutical company that lists on the OTC Bulletin Board. The Company is developing products using their proprietary Biochronomer™ polymer-based drug delivery platform. The design of this drug delivery platform is to improve the therapeutic profile of injectable pharmaceuticals through converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product is Sustol™ (formerly known as APF530). A.P. Pharma has their headquarters in Redwood City, California.
Sustol™ is undergoing development for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol™ is delivered by a single subcutaneous injection. It contains the 5-HT3 antagonist, granisetron. Granisetron, for infusion and oral tablets, is approved for the prevention of acute-onset CINV, but not delayed-onset CINV.
A.P. Pharma chose granisetron because it is a potent drug and the applicable granisetron patent expired in the United States on December 29, 2007. Granisetron was selected for Sustol™ because it is widely prescribed by physicians based on a well-established record of safety and efficacy. Sustol™ contains the 5-HT3 antagonist granisetron formulated in the Company's proprietary Biochronomer™ drug delivery system. This system allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
Today, A.P. Pharma reported that they started a program to expand the Company’s pipeline of sustained release products. This includes a new program targeting the relief of post-surgical pain. Their pain relief program employs the Company’s polymer-based Biochronomer™ drug delivery platform to continuously release anesthetic agents directly at the source of pain over a period of several days.
Additionally, A.P. Pharma announced that they will pursue a post-approval expansion of their leading drug program for the treatment of CINV with the objective of demonstrating the utility of their lead agent, Sustol™ in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents. At present, there is no approved 5-HT3 receptor antagonist for the treatment of delayed HEC.
A.P. Pharma, Inc. (APPA), closed Tuesday’s session at $0.465, up 1.09%, on 738,499 volume with 53 trades. The average volume for the last 60 days is 858,063 and the stock's 52-week low/high is $0.28/$0.887.
QUINT Media, Inc. (QUNI)
Wyatt Investment Research and Investopedia reported today on QUINT Media, Inc. (QUNI), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
QUINT Media, Inc. is a digital media company with corporate headquarters in Miami, Florida. The Company established to connect people with content relating to their passions and interests, and with each other. QUINT Media is supported by proprietary technology and a team of global experts. Effective on August 7, 2013, the Company changed their name from PediatRx, Inc. to Quint Media, Inc. to reflect their new business better. EXLEY Media, Inc. is a subsidiary of QUINT. QUINT Media’s shares trade on the OTC Markets’ OTCQB.
The Company is working to lead the digital content shift and monetize their traffic and user activity. QUINT’s brands include EXLEY®, which, in essence is, as the Company calls it, Tabloid News Reinvented. EXLEY® is re-imagining and advancing the way people consume entertainment news in a way that is as disruptive as MTV, Facebook, and TMZ were to their particular mediums. EXLEY® is powered by the QUINT Media mobile platform. The focus of EXLEY® is to transform the way people read, publish, and report gossip stories, celebrity news, as well as information.
The QUINT Media network matches people with content customized to their interests. This center of activities processes and organizes all of the information and user data across QUINT’s whole digital and social network. Feature-rich applications for iPhone, Android, and Blackberry will allow users to follow the stories that matter most to them. They can receive up-to-the-second updates on those stories as they evolve over time.
For businesses, brands, and advertisers, QUINT Media offers benefits. Benefits will be facilitated through taking advantage of user data to offer specific targeted advertising and through integrating highly effective forms of online marketing, including native and programmatic advertising, such as real-time bidding (RTB).
Yesterday, EXLEY Media announced the launch of EXLEY (www.GetExley.com). This is the first digital channel in QUINT Media's newly emerging worldwide media network. The design of EXLEY is to be a stand-out content community for lifestyle information, world entertainment news, celebrity updates, fashion, and Hollywood's hottest scoops. EXLEY is optimized for mobile.
QUINT Media, Inc. (QUNI), closed Tuesday’s trading session at $0.355, up 18.33%, on 486,210 volume with 142 trades. The average volume for the last 60 days is 8,344 and the stock's 52-week low/high is $0.0333/$0.36.
Virtual Piggy, Inc. (VPIG)
Winston Small Cap, FeedBlitz, Real Pennies, PennyTrader Publisher, and Wallstreetlivechat reported earlier on Virtual Piggy, Inc. (VPIG), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, Technology Company Virtual Piggy, Inc. is an innovator in safe youth payments. The Company is the first e-commerce solution that enables children to manage money and control their own wallet within a parent-controlled environment. Virtual Piggy delivers online security platforms designed for the Under 18 age group in the global online market. The Company has their headquarters in Hermosa Beach, California. Their online presence is at www.virtualpiggy.com.
Virtual Piggy enables parents to teach financial management via the use of a secure family wallet that is available online or through mobile. It is always 100 percent free to use. In addition, Virtual Piggy enables online businesses the ability to function in a manner consistent with the Children's Online Privacy Protection Act (COPPA) and comparable international children's privacy laws. Virtual Piggy enables the Under 18 audience to play, transact, as well as socialize in a secure online environment guided by parental permission, oversight, and control.
Virtual Piggy allows parents to set up a monthly allowance for their children. The Company promotes financial management while empowering youth under 18 to make purchasing, saving, and other money management decisions for themselves, within the boundaries set up by parents.
Last week, the Company announced that they will provide their youth-friendly payment system to Summertime Entertainment’s virtual world “Legends of Oz World.” "Legends of Oz World" serves as a prequel to the May 2014 animated feature film Legends of Oz: Dorothy’s Return. "Legends of Oz World" features multiplayer games, 30 story quests, and over 1,000 collectible items. The virtual economy in the world is powered by Live Gamer. Live Gamer is the world's foremost provider of digital commerce solutions for the interactive entertainment industry. Virtual Piggy is fully integrated into the Live Gamer framework.
Today, Virtual Piggy announced the appointment of Mr. Sébastien Motte to lead business development in the gaming sector. Mr. Motte is a gaming industry veteran. He has more than 19 years of experience in product management and business development in the game division at Microsoft (MSFT).
Mr. Motte said, “Virtual Piggy’s innovative solution will have a disruptive and sustained impact on gaming payments especially with Millenials and Generation Z. I am very excited to join this team and help grow the company’s business and partnerships in gaming and interactive entertainment markets.”
Virtual Piggy, Inc. (VPIG), closed Tuesday’s trading session at $1.04, up 2.16%, on 164,873 volume with 75 trades. The average volume for the last 60 days is 128,121 and the stock's 52-week low/high is $0.7802/$3.38.
Hangover Joe's Holding Corp. (HJOE)
Pennybuster reported earlier on Hangover Joe's Holding Corp. (HJOE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, Hangover Joe's Holding Corp. is the exclusive producer of "The Hangover" Recovery Shot. This is the official licensed product of The Hangover movie and the nation's number one selling anti-hangover recovery drink and hangover recovery product. Hangover Joe's became a publicly traded company on July 25, 2012. The Company sells their products mainly to convenience stores, liquor stores, and grocery stores via distribution agreements, and through their Website - hangoverjoes.com. The Company is based in Colorado.
Hangover Joe's product focuses on relieving the symptoms associated with alcohol induced hangovers. The product is taken the morning after; it features a patent-pending blend of antioxidants, vitamins, and herbs. Hangover Joe's is the leading Headache Recovery Shot and morning after hangover recovery product in the United States. The Company’s recovery shot helps one recover from a hangover by restoring their body with the essential antioxidants and supplements they require.
Hangover Joe’s business plan includes finalization of agreements for market expansion with major broker partners for multiple channels; secure distribution partners for global expansion; and the expansion of product offerings by way of development and introduction of new proprietary under the Hangover License and other potential licensed names.
This past September, Hangover Joe's announced that the Company has partnered with The Reese Group for Regional Grocery. Founded in 1902, The Reese Group is a leading regional independent broker. They have 16 offices and cover 36 states, with coverage of more than 25,000 stores and relationships that reach the channels of Supermarket, Specialty Food, Military, as well as Dollar Discount.
Furthermore, Hangover Joe’s announced in September that they also partnered with the USA's largest Broker for Convenience Stores. This company's leadership in the industry and strong management team, combined with its notable track record of developing client businesses, has positioned the broker as a leading player.
Hangover Joe's Holding Corp. (HJOE), closed Tuesday’s trading session at $0.025, up 31.58%, on 3,666,721 volume with 249 trades. The average volume for the last 60 days is 113,575 and the stock's 52-week low/high is $0.0117/$0.20.
Victory Energy Corp. (VYEY)
The QualityStocks Daily Newsletter would like to spotlight Victory Energy Corp. (VYEY). Today, Victory Energy Corp. closed trading at $0.20, even with yesterday's close, on 6,600 volume with 6 trades. The stock’s average daily volume over the past 60 days is 840, and its 52-week low/high is $0.0136/$0.50.
Victory Energy Corp. today announced it will double in size for the 2013 fiscal year and is poised for significant growth with currently held Permian Basin properties. Undiscounted proved reserves are expected to exceed $6.6 million for the 2013 reporting period, delivering a significant impact on current and future revenue. Victory Energy also released historical restated financials and a new investor presentation on the company website.
Victory Energy Corp. (VYEY) is an independent, growth-oriented oil and gas company focused on growing proved reserves and cash-flow via the continued development of existing properties and the acquisition of new resource properties, primary located in the prolific Permian Basin of Texas and southeast New Mexico. The Company will source new capital to facilitate this growth by continuing to utilize an established pipeline of investors available through Aurora Energy Partners and additional third-party sources. The company is committed to creating long-term shareholder value by increasing oil reserves, lowering costs, boosting production volumes, and prudently managing the capital on its balance sheet.
The company is geographically focused onshore, with a primary emphasis on the Permian Basin of Texas and southeast New Mexico. Victory strategically utilizes both internal capabilities and strategic industry relationships to acquire non-operated working interest positions in low-to-moderate risk oil and gas prospects. Its focus is on oil or liquid-rich gas projects within longer-life reservoirs that offer competitive finding and development (F&D) costs per barrel of oil equivalent (BOE).
Victory’s carefully assembled management team has more than 120 years of direct and relevant oil and gas experience. The company also utilizes a team of third-party professionals on an as-needed basis. This team includes geologists for property evaluation and assessment and reservoir engineering resources for the analysis of current and new properties. Reserve reporting is performed by a third-party engineer located in Midland, Texas. Each independent operator utilized by the company also has their own array of experts.
As it executes its strategy, Victory will be targeting investment in larger working interest projects (10%-25% that are weighted toward oil and high-BTU natural gas. This approach of increasing economic interest should allow for improved returns through cost efficiencies derived from economies of scale. Lower expenses and additional capital will give the company added flexibility to invest in the development of its current proven undeveloped, possible, and probable reserves, while also allowing for additional oil and gas prospects and improved working interest positions. Disclaimer
Victory Energy Corp. Company Blog
Victory Energy Corp. News:
Victory Energy Corporation Doubles in Size
Victory Energy Appoints New Board Member
Victory Energy Significantly Increases Daily Production and Proved Reserves
Sohm, Inc. (SHMN)
The QualityStocks Daily Newsletter would like to spotlight Sohm, Inc. (SHMN). Today, Sohm, Inc. closed trading at $0.0042, up 50.00%, on 211,494 volume with 9 trades. The stock’s average daily volume over the past 60 days is 294,581, and its 52-week low/high is $0.0021/$0.013.
Sohm, Inc. today announced the U.S. launch of their umbrella brand, "SohMed™," positioning the company with a firm foothold in the generic over-the-counter (OTC) medicines segment for indications of pain, fever, cold, antacid and alertness. Shailesh Shah, president and CEO of SOHM, stated, "SOHM believes in providing low-cost quality medicines to its customers and the SohMed™ range of generic medicines will thus be made available in the United States through a nationwide network of distributors, warehouse stores, convenience stores and more."
Sohm, Inc. (SHMN) is a globally recognized pharmaceutical manufacturer that develops, manufactures, and distributes generic, private label, and Sohm-innovated pharmaceutical, cosmeceutical, and nutraceutical products. The company exports product worldwide, with a focus on distribution in emerging markets such as Africa, Latin America, and Southeast Asia.
In 2012, Sohm was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people’s lives in every corner of the world, the company has U.S. headquarters in Buena Park, CA, with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.
Research and development activities capitalize on the company’s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.
To ensure regulatory compliance, the company continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, Sohm is well positioned to continue its rapid growth.. Disclaimer
Sohm, Inc. Company Blog
Sohm, Inc. News:
SOHM Launches SohMed(TM) Range of Branded OTC Medicines in U.S. Market
Sohm, Inc. CEO Featured in Exclusive QualityStocks Interview
SOHM, Inc. Announces Engagement of QualityStocks Investor Relations Services
Boston Therapeutics, Inc. (BTHE)
The QualityStocks Daily Newsletter would like to spotlight Boston Therapeutics, Inc. (BTHE). Today, Boston Therapeutics, Inc. closed trading at $1.52, up 9.35%, on 6,525 volume with 7 trades. The stock’s average daily volume over the past 60 days is 13,317, and its 52-week low/high is $0.15/$1.65.
Boston Therapeutics, Inc. today began enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. The study is being conducted at Centre Hospitalier Robert Bisson, Lisieux, France and the primary endpoint of the study is the evaluation of the effect of PAZ320 compared to placebo in the area under the curve (AUC) of glucose and on insulin levels in the blood for four hours following intake of the meal.
Boston Therapeutics, Inc. (BTHE) is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.
PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics believes PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need. PAZ320 has completed a Phase ll clinical trial at Dartmouth Medical Center. 45% of the patients responded with a 40% reduction in the elevation of post meal blood sugar compared to baseline with no serious adverse events.
IPOXYNT, a universal oxygen carrier, is an injectable Rx for prevention of necrosis and treatment of ischemic conditions which may lead to necrosis. This compound is not a biologic, but a second generation New Chemical Entity HBOC (hemoglobin based oxygen carrier). The potential for this product goes well beyond Lower Limb Ischemia into a range of areas from anemia and blood loss (injury), to cardiovascular disease and surgical blood supplementation.
The Boston Therapeutics management and advisory team has extensive expertise in complex carbohydrate chemistry, regulatory affairs, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Backed by a team with more than five decades of expertise in public and private business management, the company is well positioned to advance its status as a premier developer of complex carbohydrate-based new chemical entities. Disclaimer
Boston Therapeutics, Inc. Company Blog
Boston Therapeutics, Inc. News:
Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320
Boston Therapeutics to Present at the Livingston Securities Advanced and Nano Life Sciences Summit
Boston Therapeutics Initiates Research Study on PAZ320 at University of Minnesota
First Titan Corp. (FTTN)
The QualityStocks Daily Newsletter would like to spotlight First Titan Corp. (FTTN). Today, First Titan Corp. closed trading at $9.25, up 7.70%, on 162,773 volume with 109 trades. The stock’s average daily volume over the past 60 days is 162,773, and its 52-week low/high is $0.29/$2.50.
First Titan Corp. reported today on continued efforts to build its growing oil and gas energy portfolio, detailing the company's evaluation of a potentially lucrative oil production deal in Rusk County, Texas. Located in East Texas near Kilgore, Rusk County is a fertile oil patch with over 12,000 wells and more than 650 producing operators in the area. In May, there were 151,172 barrels of oil and almost 9 million cubic feet of gas produced.
First Titan Corp. (FTTN), is currently focused on exploring and developing oil and natural gas resources in the southern region of the United Sates, but has a worldwide growth strategy in place. The company continually seeks to partner with energy developers that are pursuing innovative new methods of oil and gas extraction, including the development of new technologies, cleaner methods, and unconventional resources.
First Titan has acquired multiple working interests with established oil exploration companies to deliver new hydrocarbons to an ever-growing market. As the company maintains drilling activities at its acquisition in South Lake Charles, Louisiana, it is looking to continue adding to its asset base that includes five new wells along the Gulf Coast, from West Texas to Alabama.
Global demand for energy is rising fast as the vehicle populations of emerging nations such as China, Brazil, and India continue to soar. U.S. exports of petroleum products have reached 2.6 million barrels a day, which is double the level of three years ago. As demand for global energy resources rises, the U.S. is poised to become an international supplier.
New innovations in drilling and rising global demand have positioned First Titan as a premier early-stage company with strong growth potential. By utilizing cutting-edge technology to extract oil and gas resources, the company is able to recover fossil fuels that were once considered too difficult or too expensive to recover. Disclaimer
First Titan Corp. Company Blog
First Titan Corp. News:
FTTN: Targeting New Assets in East Texas
FTTN: Billion Dollar GTL Market Continues Expansion as Competitive Dynamics Sway in Favor
FTTN: Drilling Continues Past 12,000 Feet in South Lake Charles
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.35, up 2.91%, on 966,089 volume with 268 trades. The stock’s average daily volume over the past 60 days is 890,919, and its 52-week low/high is $0.20/$3.50.
Pan Global Corp. was pleased to announce today that through its wholly-owned subsidiary, Pan Asia Infratech, Corp., the Company's plans for developing an environmentally sustainable greenhouse growing operation in Punjab, India are proceeding as planned and on schedule. Preliminary research indicates there is a large market for the company's planned greenhouse vegetable production, where product is of higher quality, available on a more consistent schedule and has favorable environmental attributes such as limited or no use of chemical fertilizer and up to 90% less use of water.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global Corp. Outlines Plans for Its Sustainable Greenhouse Business
Pan Global Corp. Shareholder Update: Pre-Closing Requirements to Acquire Small-Hydro Project on Track
Pan Global Corp. Enters Into Definitive Agreement to Acquire 100% of 5.7MW Small-Hydro Plant in India
Kallo, Inc. (KALO)
The QualityStocks Daily Newsletter would like to spotlight Kallo, Inc. (KALO). Today, Kallo, Inc. closed trading at $0.04, even with yesterday's close, on 134,250 volume with 9 trades. The stock’s average daily volume over the past 60 days is 38,880, and its 52-week low/high is $0.0116/$0.05.
Kallo, Inc. today announced that the Monsieur Directeur Général de l'Administration et Controle des Grands Project (ACGP) Guinea has officially confirmed final discussions with the Company on financing, contracts and delivery timelines of Kallo MobileCare™. The confirmed itinerary commences on Monday, November 18, 2013, with a presentation on implementation of Kallo MobileCare™, with service, maintenance, education and training discussed on the following day, and project financing, as well as delivery timelines to be finalized by the end of the week.
Kallo, Inc. (KALO) leverages a suite of technologies to improve the quality and efficiency of care in the $6.3 trillion global healthcare industry. Offering centralized, congruent solutions that attend healthcare and business issues, the company addresses the needs of hospitals, ministries of health, physicians, and other healthcare organizations.
As a result of an expanding and aging population, coupled with an increasing number of people suffering from chronic diseases and lifestyle related conditions, healthcare expenditures continue to grow. Kallo is focused on introducing new healthcare technology that helps contain costs, enable better methods to monitor/treat medical conditions, and increase the reach of healthcare providers to remote areas.
The tailored solutions offered by Kallo complement existing infrastructure, workflows, and processes, increasing both uptime and productivity. The company’s suite of products complies with international, national, and regional standards, and its stringent quality control ensures repeatable, process-driven delivery for maximum performance.
Kallo’s executives and directors bring rich and diverse industry knowledge. Collectively, the management team reflects the strength of the company’s global network and the diversity of its global culture. The team’s entrepreneurship, passion, experience, and knowledge of healthcare enables Kallo to continually deliver higher standards. Disclaimer
Kallo, Inc. Company Blog
Kallo, Inc. News:
Kallo to Negotiate Implementation Strategy of MobileCare(TM) With Guinea Government Officials
Kallo MobileCare(TM) - Update From Republique De Guinee
KALO Announces More Distribution Areas
Global Payout, Inc. (GOHE)
The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.08, on 3,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 33,032, and its 52-week low/high is $0.03/$0.15.
Global Payout, Inc. was announced today by QualityStocks as having a new and exclusive audio interview with the company. CEO James Hancock now available. The interview can be heard at http://qualitystocks.net/interview-gohe.php and covers details of Global Payout's early stages, its emergence onto the global scene as a provider of electronic and pre-paid payment solutions that can be used by companies worldwide, as well as milestones achieved in 2013 like the launch of Global Payout's MoneyTrac™ consolidated payment gateway and the formation of strategic partnerships with international issuing banks to offer pre-paid cards outside the United States.
Global Payout, Inc. (GOHE) specializes in customized payment solutions for businesses and organizations worldwide. The company’s global network of banks and processing partners enable companies and organizations to efficiently deploy a customized payment solution configured specifically for each client. From solving a single payment issue to meeting an entire global payment requirement, Global Payout in conjunction with its partners delivers modular payment solutions.
Global Payout has a product line of prepaid "off the shelf" products that can be utilized or Global Payout can customize payment solutions for qualified businesses. By coupling its network of international banks and third-party processing relationships with an innovative payment platform, Global Payout enables organizations to "plug into" an efficient and cost effective method of paying employees, contractors, investors, and commissioned agents wherever they might be located in the world.
Global Payout began operations as a business to business provider of pre-paid debit cards for payroll and general spend programs. The company then launched a Prepaid Discover® card to meet the demand of its business clients in the United States. As a result of these efforts and with the input of their client base, Global Payout then greatly extended its reach by developing a new proprietary “payment platform” which enables companies and organizations to make necessary payments in every country a company does business. Clients can now make international payments without the need to establish banking relationships in each and every country they do business. Businesses now have an efficient, compliant and simplified system to make their all necessary international payments using Global Payout’s proprietary payment platform.
Global Payout delivers dependable and secure global payment solutions for companies worldwide. This relieves clients of burdensome and time consuming efforts to establish banking relationships everywhere they do business. The company’s “consolidated payment gateway” product can be configured specifically to the needs of each client within a short period of time. Global Payout is led by a management team comprised of pioneers in domestic and international payment delivery solutions. The company is well positioned to leverage their long standing international financial relationships to expand their services and global reach. Even during this expansion, Global Payout remains committed to serving domestic and international clients and providing them with customized one-stop solutions that address each client’s specific payment needs. Disclaimer
Global Payout, Inc. Company Blog
Global Payout, Inc. News:
Global Payout, Inc. CEO Featured in Exclusive QualityStocks Interview
Global Payout, Inc. Announces Engagement of QualityStocks Investor Relations Services
ImageWare Systems Provides Next Generation Cloud Identity Management and Authentication Services to Global Payout's MoneyTracTM Consolidated Payment Gateway
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.3501, up 11.71%, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,497, and its 52-week low/high is $0.25/$0.90.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Provides Update on $36 Million Strategic Financing Agreement
VistaGen Therapeutics Presents CardioSafe 3D and LiverSafe 3D Developments at International Society of Stem Cell Research's 11th Annual Meeting
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Big Tree Group, Inc. (BIGG) Announces Engagement of QualityStocks Investor Relations Services
- Boston Therapeutics, Inc. (BTHE) Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320
- CD International Enterprises, Inc. (CDII) and Manali Engineering-India Complete Magnesium Distribution Agreement
- Calpian, Inc. (CLPI) Subsidiary Money-on-Mobile Honored with Two Prestigious Awards
- Consorteum Holdings, Inc. (CSRH) Forms a New, Wholly Owned Subsidiary
- eCrypt Technologies, Inc. (ECRY) CEO Featured in Exclusive QualityStocks Interview
- First Titan Corp. (FTTN) Targeting New Assets in East Texas
- Global Payout, Inc. (GOHE) CEO Featured in Exclusive QualityStocks Interview
- GlobalWise Investments, Inc. (GWIV) Announces Participation in Innovation Fair in Tokyo 2013
- Intelimax Media, Inc. (IXMD) Launches New Daily Fantasy Sports Platform on DraftTeam.com
- International Stem Cell Corp. (ISCO) to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
- Kallo, Inc. (KALO) to Negotiate Implementation Strategy of MobileCare(TM) With Guinea Government Officials
- Mabwe Minerals Inc. (MBMI) Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification
- Max Sound Corp. (MAXD) MAX-D® HD Delivers Audio Perfection Experience on Snapdragon® DSP
- Midwest Energy Emissions Corp. (MEEC) SEA™ Technology Featured in Energy-Tech Magazine
- NanoTech Entertainment, Inc. (NTEK) Proven Successful for Streaming 4K Content at American Film Market 2013
- Nexus Enterprise Solutions, Inc. (NXES) Catapults into Profitability
- On the Move Systems, Inc. (OMVS) Targets New Transportation Clientele
- OxySure Systems, Inc. (OXYS) Oxygen Biotherapeutics Rise Sheds Light On OxySure Systems
- Pan Global, Corp. (PGLO) Outlines Plans for Its Sustainable Greenhouse Business
- Raptor Resources Holdings Inc. (RRHI) Mabwe Minerals Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification
- Sohm, Inc. (SHMN) Launches SohMed(TM) Range of Branded OTC Medicines in U.S. Market
- Singlepoint, Inc. (SING) Announces Moody Bible Institute to White Label Technology for Mobile Donations, SMS Capabilities
- StreamTrack, Inc. (STTK) Announces Cancellation of Potential $2.5 Million Royalty Liability
- VistaGen Therapeutics, Inc. (VSTA) Provides Update on $36 Million Strategic Financing Agreement
- Victory Energy Corp. (VYEY) Doubles in Size